Effect of dermatological consultation on survival in patients with checkpoint inhibitor‐associated cutaneous toxicity
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of dermatological consultation on survival in patients with checkpoint inhibitor‐associated cutaneous toxicity
Authors
Keywords
-
Journal
BRITISH JOURNAL OF DERMATOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-03-18
DOI
10.1111/bjd.20074
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
- (2020) Nasser H. Hanna et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of Point-of-Care Decision Support for Adult Acne Treatment by Primary Care Clinicians
- (2020) David G. Li et al. JAMA Dermatology
- CME Part II: Immune checkpoint inhibitor-related dermatologic adverse events
- (2020) Amaris N. Geisler et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Understanding Propensity Score Analyses
- (2020) Nafisha Lalani et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Telemedicine usability for cancer care during the COVID-19 pandemic.
- (2020) Christian Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
- (2019) John A. Thompson et al. Journal of the National Comprehensive Cancer Network
- Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.
- (2019) Takashi Kojima et al. JOURNAL OF CLINICAL ONCOLOGY
- Patient‐centered engagement and symptom/toxicity monitoring in the new era of tumor next‐generation sequencing and immunotherapy: The OncoTool and OncoPRO platforms
- (2019) Betina Yanez et al. CANCER
- Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Hyun Cheol Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of Anti–Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma
- (2019) Henry T. Quach et al. JAMA Oncology
- Treatment Outcomes of Immune-Related Cutaneous Adverse Events
- (2019) Gregory S. Phillips et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- Dermatology Consultation Reduces Interruption of Oncologic Management Among Hospitalized Patients with Immune-related Adverse Events: A Retrospective Cohort Study
- (2019) Steven T. Chen et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
- (2019) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
- (2019) Robert J Motzer et al. LANCET ONCOLOGY
- Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies
- (2019) Yun-He Wang et al. MOLECULAR PSYCHIATRY
- Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
- (2019) Satya Das et al. Journal for ImmunoTherapy of Cancer
- Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study
- (2019) D.M. Barrios et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study
- (2018) Charles Kyung Min Lee et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma
- (2018) Sandra P. D’Angelo et al. JAMA Oncology
- Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
- (2018) Koji Haratani et al. JAMA Oncology
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institutional, retrospective analysis with stratification of reactions by toxicity and implications for management
- (2018) Emily Coleman et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy
- (2018) Paolo A. Ascierto et al. JAMA Oncology
- Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
- (2017) Robert Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
- (2017) Arjun V Balar et al. LANCET ONCOLOGY
- Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
- (2016) V.R. Belum et al. EUROPEAN JOURNAL OF CANCER
- Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
- (2016) Jonathan L. Curry et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Research letter: Impact of pruritus on quality of life—A systematic review
- (2016) Robert Kantor et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
- (2015) J. Naidoo et al. ANNALS OF ONCOLOGY
- The cutaneous side-effect iceberg
- (2015) S. Walsh BRITISH JOURNAL OF DERMATOLOGY
- Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial
- (2015) Marie A. Bakitas et al. JOURNAL OF CLINICAL ONCOLOGY
- Palliative Care for the Seriously Ill
- (2015) Amy S. Kelley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
- (2015) Martina Sanlorenzo et al. JAMA Dermatology
- Patient-Centered, Direct-Access Online Care for Management of Atopic Dermatitis
- (2015) April W. Armstrong et al. JAMA Dermatology
- The thresholds for statistical and clinical significance – a five-step procedure for evaluation of intervention effects in randomised clinical trials
- (2014) Janus Christian Jakobsen et al. BMC Medical Research Methodology
- Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods
- (2014) Janus Christian Jakobsen et al. BMC Medical Research Methodology
- False discovery rate control is a recommended alternative to Bonferroni-type adjustments in health studies
- (2014) Mark E. Glickman et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Factors Mediating the Impact of Chronic Pruritus on Quality of Life
- (2014) Christopher W. Carr et al. JAMA Dermatology
- International validation of the EORTC QLQ-ELD14 questionnaire for assessment of health-related quality of life elderly patients with cancer
- (2013) S Wheelwright et al. BRITISH JOURNAL OF CANCER
- Sleep and immune function
- (2011) Luciana Besedovsky et al. PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
- Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
- (2010) Jennifer S. Temel et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More